Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TPH1 | P17752 | 1/20 | 0.53 |
| ▸ | GRB2 | P62993 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231560 | 1.00 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29141465 | 0.87 | ITGB3 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL27793245 | 0.86 | SLC7A5 (0.44) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL27793243 | 0.86 | SLC7A5 (0.44) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29098298 | 0.85 | SLC7A5 (0.53) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2310526 | 0.84 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23069008 | 0.83 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23069010 | 0.83 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL27793227 | 0.83 | GRIK1 (0.49) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL93952 | 0.82 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AMBRX, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250327074-A1 | THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS | SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) | 2025-10-23 | — | — | US | claimed |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | claimed |
| US-12404512-B2 | Method for optimizing antibody expression | AMBRX, INC. (US) | 2025-09-02 | — | — | US | claimed |
| EP-3788149-B1 | A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION | AMBRX INC (US) | 2025-08-27 | — | — | EP | claimed |
| US-12377131-B2 | Cytokine conjugates for the treatment of autoimmune diseases | Synthorx, Inc. (US) | 2025-08-05 | — | — | US | claimed |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | AMBRX, INC. (US) | 2025-08-05 | — | — | US | claimed |
| US-12318431-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Synthorx, Inc. (US) | 2025-06-03 | — | — | US | claimed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| EP-3630977-A1 | METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION | Ambrx, Inc. (US) | 2020-04-08 | — | — | EP | claimed |
| WO-2020047176-A1 | ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES AND THEIR USES | AMBRX, INC. (US) | 2020-03-05 | — | — | WO | claimed |
| WO-2019191728-A1 | HUMANIZED ANTI-PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | AMBRX, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| US-10428333-B2 | Non-natural amino acid replication-dependent microorganisms and vaccines | AMBRX INC. (US) | 2019-10-01 | — | — | US | claimed |
| WO-2019028419-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | claimed |
| WO-2019028425-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | claimed |
| WO-2018223108-A1 | METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION | AMBRX, INC. (US) | 2018-12-06 | — | — | WO | claimed |
| EP-2337846-B1 | NON-NATURAL AMINO ACID REPLICATION-DEPENDENT MICROORGANISMS AND VACCINES | AMBRX INC (US) | 2018-01-17 | — | — | EP | claimed |
| US-9121024-B2 | Non-natural amino acid replication-dependent microorganisms and vaccines | AMBRX, INC. (US) | 2015-09-01 | — | — | US | claimed |
| US-9121025-B2 | Non-natural amino acid replication-dependent microorganisms and vaccines | AMBRX, INC. (US) | 2015-09-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428333-B2 | Non-natural amino acid replication-dependent microorganisms and vaccines | BCAT2, IFNG, AADAT | SLC7A5 233/4885PTGS1 3543/4885ALPI 3402/4885 |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | SLC7A5 2484/4885PTGS1 1447/4885ALPI 1243/4885 |
| US-12318431-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | IL2, IL2RA, IL36G | SLC7A5 1836/4885PTGS1 1611/4885ALPI 506/4885 |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | FOLR2, FOLR1, CD2 | SLC7A5 271/4885PTGS1 4505/4885ALPI 1217/4885 |
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AARS1, NSUN3, UPF1 | SLC7A5 136/4885PTGS1 4736/4885ALPI 2459/4885 |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | SLC7A5 1836/4885PTGS1 1611/4885ALPI 506/4885 |
| US-12377131-B2 | Cytokine conjugates for the treatment of autoimmune diseases | IL2, IL2RA, IL15 | SLC7A5 2484/4885PTGS1 1447/4885ALPI 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.